{"doi":"10.1002/9781119220787.ch153","title":"SEROMYCIN (Cycloserine)","abstract":null,"journal":"Antibiotics Manual","year":2017,"id":688471,"datarank":0.10397207708399181,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.0,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"SEROMYCIN (Cycloserine)","abstract":"This chapter provides the basic characteristics, side effects/toxicity, drug interactions, and dosage information of the Seromycin (Cycloserine). Cycloserine inhibits cell-wall synthesis in gram-positive and gram-negative bacteria and in Mycobacterium tuberculosis. Treatment of active pulmonary and extrapulmonary tuberculosis when the causative organisms are susceptible to this drug and when treatment with the primary medications has proved inadequate. Treatment of active pulmonary and extrapulmonary tuberculosis when the causative organisms are susceptible to this drug and when treatment with the primary medications has proved inadequate. Cycloserine should never be used alone in the treatment of active tuberculosis. Cycloserine should only be used if resistance to first line antimycobacterial agents is noted. Cycloserine may cause increased neurotoxic side effects when administered with ethionamide. Neuropsychiatric side effects usually occur at serum levels >35 mcg/mL; serum levels of cycloserine should be monitored, with a goal of peak levels of 20-35 mcg/mL. Hematologic, renal, and hepatic functions should be monitored.","is_dataset_classified":null,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21097893","pmcid":null,"openalex_id":"https://openalex.org/W4245753501","authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[{"year":2015,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F9781119220787.ch153","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781119220787.ch153","host_type":"publisher"},{"url":"https://doi.org/10.1002/9781119220787.ch153","host_type":""}],"fields_of_study":["Cancer therapeutics and mechanisms","Synthesis and Biological Evaluation","Tuberculosis Research and Epidemiology"],"mesh_terms":[],"keywords":["Cycloserine","Ethionamide","Mycobacterium tuberculosis","Drug","Tuberculosis","Antibiotics","Medicine","Pharmacology","Pulmonary tuberculosis","Microbiology","Biology","Pathology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-19T16:31:03.107683Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}